Rating Change
William Blair analysts initiated coverage on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a rating of Outperform on October 16, 2026.
new coverageNASDAQ:RYTM
William Blair Initiates Coverage on Rhythm Pharmaceuticals, Inc. (RYTM) with Outperform
William Blair analysts initiated coverage on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a rating of Outperform on October 16, 2026.
At publication ·
What changed
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) · new coverage
- Firm
- William Blair
- Rating
- Outperform
- Price at event
- $87.90
- Market capitalization
- $7.8B
At a glance
Key takeaways
- William Blair initiated Outperform coverage on Rhythm Pharmaceuticals (RYTM) on October 16, 2026, with the stock trading at $87.90 and a market cap of $7.8 billion.
Market Context
Rhythm Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $87.90 with a market capitalization of $7.8B. The stock has declined 22.9% over the past 52 weeks.
Analyst coverage from William Blair provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Rhythm Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Rhythm Pharmaceuticals, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 16, 2026 | William Blair | Outperform | N/A |
| Oct 15, 2026 | JP Morgan | Overweight | N/A |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 08, 2026 | RBC Capital | Outperform | N/A |
| Aug 28, 2026 | Deutsche Bank | Hold | N/A |
Related Tools: Analyst Ratings Dashboard | View RYTM Stock Page
Frequently Asked Questions
What does the Outperform rating mean for RYTM?
A rating of Outperform from William Blair reflects the analyst's outlook on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RYTM forecast page.